Valuation: Hangzhou Tigermed Consulting Co., Ltd

Capitalization 41.98B 5.76B 5.51B 5.21B 4.59B 8.18B 499B 9.14B 61.99B 23B 208B 21.57B 21.14B 880B P/E ratio 2024 *
94.9x
P/E ratio 2025 * 25.2x
Enterprise value 36.26B 4.97B 4.76B 4.5B 3.97B 7.07B 431B 7.89B 53.55B 19.87B 180B 18.63B 18.26B 760B EV / Sales 2024 *
5.32x
EV / Sales 2025 * 4.58x
Free-Float
72.37%
Yield 2024 *
0.67%
Yield 2025 * 0.89%
More valuation ratios * Estimated data
Dynamic Chart
Tigermed Consulting Forecasts Up to 81% Lower Attributable Net Profit for 2024 01-27 MT
Hangzhou Tigermed Consulting Co., Ltd Provides Earnings Guidance for the Year Ended December 31, 2024 01-24 CI
Tranche Update on Hangzhou Tigermed Consulting Co., Ltd's Equity Buyback Plan announced on May 24, 2024. 01-06 CI
Hangzhou Tigermed Consulting Books 35% Lower Attributable Profit in Q3 24-10-29 MT
Frontage Records Lower Net Profit for Nine Months to September 24-10-29 MT
Hangzhou Tigermed Consulting Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2024 24-10-29 CI
Tranche Update on Hangzhou Tigermed Consulting Co., Ltd's Equity Buyback Plan announced on May 24, 2024. 24-10-09 CI
Hangzhou Tigermed Consulting Co., Ltd agreed to acquire 3.69% stake in Teddy Clinical Research Laboratory Co., Ltd from Suzhou Yingkai Xinyun Enterprise Management Consulting Co., Ltd. for CNY 12.9 million. 24-09-26 CI
Hangzhou Tigermed Consulting Co., Ltd agreed to acquire 5.22% stake in Zhuji Guanhe Enterprise Management Partnership Enterprise (L.P.) from Dian Diagnostics Group Co.,Ltd. for CNY 1.4 million. 24-09-26 CI
Hangzhou Tigermed Consulting Co., Ltd agreed to acquire 35.83% stake in Teddy Clinical Research Laboratory Co., Ltd from Dian Diagnostics Group Co.,Ltd. for approximately CNY 130 million. 24-09-26 CI
Nomura Adjusts Hangzhou Tigermed Consulting's Price Target to 47.29 Yuan From 50.75 Yuan, Keeps at Neutral 24-08-29 MT
Nomura Adjusts Hangzhou Tigermed Consulting's Price Target to HK$28.56 From HK$30.65, Keeps at Neutral 24-08-29 MT
Hangzhou Tigermed Consulting's H1 Profit Falls 65% 24-08-29 MT
More news
1 day-1.05%
1 week+4.89%
Current month+7.63%
1 month+6.20%
3 months-21.98%
6 months-2.75%
Current year-3.44%
More quotes
1 week
51.55
Extreme 51.55
54.80
1 month
47.80
Extreme 47.8
54.80
Current year
47.80
Extreme 47.8
57.13
1 year
40.83
Extreme 40.83
82.79
3 years
36.12
Extreme 36.12
134.80
5 years
36.12
Extreme 36.12
209.41
10 years
14.05
Extreme 14.05
209.41
More quotes
Director TitleAgeSince
Chief Executive Officer 55 -
Director of Finance/CFO 51 2022-10-20
President 57 2019-12-31
Manager TitleAgeSince
Director/Board Member 55 2004-12-31
Chairman 62 -
Director/Board Member 65 -
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi.($)
-1.05%+4.89%+23.22%-40.47% 5.81B
-0.10%-2.45%+35.29%-2.61% 47.29B
-0.89%-6.63%-8.93%-19.74% 34.84B
-0.45%-1.71%-0.38%+22.57% 26.05B
-0.08%+4.72%+73.31%+81.97% 16.55B
-2.09%-6.79%-33.62%-30.17% 15.4B
+4.54%-5.03%-62.61%-80.21% 11.75B
+13.36%+28.87% - - 11.63B
-0.99%-10.99%-1.11%-36.19% 10.66B
+1.77%-5.14%-5.96%+95.77% 10.25B
Average +0.20%-0.54%+2.14%-1.01% 19.02B
Weighted average by Cap. -0.06%-1.25%+7.67%+0.49%
See all sector performances

Financials

2024 *2025 *
Net sales 6.82B 935M 896M 846M 746M 1.33B 81.1B 1.48B 10.07B 3.74B 33.76B 3.51B 3.44B 143B 7.73B 1.06B 1.01B 958M 845M 1.51B 91.86B 1.68B 11.41B 4.23B 38.25B 3.97B 3.89B 162B
Net income 1.14B 156M 149M 141M 124M 221M 13.5B 247M 1.68B 622M 5.62B 584M 572M 23.82B 1.6B 219M 210M 199M 175M 312M 19.03B 348M 2.36B 877M 7.92B 823M 806M 33.57B
Net Debt -5.72B -784M -751M -709M -625M -1.11B -67.97B -1.24B -8.44B -3.13B -28.3B -2.94B -2.88B -120B -6.62B -908M -870M -822M -724M -1.29B -78.76B -1.44B -9.78B -3.63B -32.79B -3.4B -3.34B -139B
More financial data * Estimated data
Logo Hangzhou Tigermed Consulting Co., Ltd
Hangzhou Tigermed Consulting Co, Ltd. specialises in providing professional services to pharmaceutical and biotech companies. The group supports its clients in all processes of clinical development and product commercialization. Net sales break down by activity as follows: - provision of clinical trial services and related technological services (51.8%); - provision of clinical research consulting services (48.2%). China accounts for 46% of sales.
Employees
-
Calendar
More about the company
Date Price Change Volume
25-02-13 52.74 ¥ -1.05% 9,960,587
25-02-12 53.30 ¥ +0.57% 8,358,500
25-02-11 53.00 ¥ -3.07% 12,594,070
25-02-10 54.68 ¥ +5.70% 21,462,350
25-02-07 51.73 ¥ +2.88% 21,056,220

End-of-day quote Shenzhen S.E., February 12, 2025

More quotes
Trading Rating
Investor Rating
ESG MSCI
AA
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
52.74CNY
Average target price
59.17CNY
Spread / Average Target
+12.19%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. 300347 Stock